InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
1
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Merck & Co., Inc.. Director active across 3 companies, notably Organon & Co.. Cumulatively, 5 reports have been logged. Split: 1 buy · 0 sell. Total volume traded: €449.7m. Activity tracked since 11 March 2024. The latest transaction was filed on 11 March 2024 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Merck & Co., Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报5 总计
21,397,205 股@ US$23.00100.0% 占其流量Common Stock, par value $0.0001SEC:0000950170-24-029165:0
标准退出：2024年6月9日 (T+90)
253,516,000 股Common StockSEC:0000899243-21-022060:0
18,518,519 股Ordinary SharesSEC:0001635698-16-000062:0
5,128,205 股Ordinary SharesSEC:0001635698-16-000062:1
7,942,314 股Ordinary SharesSEC:0001635698-16-000062:2
5 条申报中的 5 条
About Merck & Co., Inc.
Merck & Co., Inc. is a declarant with 6 filings in total. In the recent filings sampled, buys total 449728354 EUR, sells are 0 EUR, and the date range runs from 2016-02-10 to 2024-03-11. The companies mentioned are BeiGene, Ltd., Organon & Co., and Harpoon Therapeutics, Inc.
